Currently out of the existing stock ratings of Mathew Blackman, 43 are a HOLD (37.72%), 71 are a BUY (62.28%).

Mathew Blackman

Work Performance Price Targets & Ratings Chart

Analyst Mathew Blackman, currently employed at STIFEL, carries an average stock price target met ratio of 70.33% that have a potential upside of 27.14% achieved within 130 days.

Mathew Blackman’s has documented 225 price targets and ratings displayed on 17 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GMED, Globus Medical at 09-May-2025.

Wall Street Analyst Mathew Blackman

Analyst best performing recommendations are on CLPT (CLEARPOINT NEURO).
The best stock recommendation documented was for DXCM (DEXCOM) at 10/22/2019. The price target of $47.5 was fulfilled within 16 days with a profit of $9.78 (25.93%) receiving and performance score of 16.2.

Average potential price target upside

of $17.4 (21.26%) on DXCM (DEXCOM).
of $16.94 (6.76%) on PODD (INSULET).
of $9.69 (9.69%) on TNDM (TANDEM DIABETES CARE).

AHCO Adapthealth Corp ATEC Alphatec Holdings CERS Cerus DXCM DexCom GMED Globus Medical NUVA NuVasive OFIX Orthofix Medical SENS Senseonics Holdings SPNE SeaSpine Holdings Corp CSII Cardiovascular Systems ELGX Endologix INGN Inogen APEN Apollo Endosurgery PODD Insulet TNDM Tandem Diabetes Care WMGI Wright Medical Group N.V CLPT Clearpoint Neuro

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Richard Close (CANACCORD)